相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Predictive Value of Lp(a) for Adverse Cardiovascular Event in ACS Patients With an Achieved LDL-C Target at Follow Up After PCI
Yongkui Ren et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2022)
Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990-2017: results from the Global Burden of Disease Study 2017
Haijiang Dai et al.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2022)
Lp(a): When and how to measure it
Jaimini Cegla et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2021)
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
Ron C. Hoogeveen et al.
CLINICAL CHEMISTRY (2021)
Satin therapy increases lipoprotein(a) levels
Sotirios Tsimikas et al.
EUROPEAN HEART JOURNAL (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
The 'Ten Commandments' for the 2020 ESC Guidelines for themanagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Jean-Philippe Collet et al.
EUROPEAN HEART JOURNAL (2020)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael Szarek et al.
EUROPEAN HEART JOURNAL (2020)
Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-The Framingham Heart Study
Mehdi Afshar et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael Szarek et al.
EUROPEAN HEART JOURNAL (2020)
Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes
Baris Gencer et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2019)
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association
Jennifer G. Robinson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
Hayato Tada et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials
Amirhossein Sahebkar et al.
SCIENTIFIC REPORTS (2018)
Acute myocardial infarction in patients with ST-segment elevation myocardial infarction. ESC guidelines 2017
H. Thiele et al.
HERZ (2017)
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN
Rishi Puri et al.
ATHEROSCLEROSIS (2017)
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome
Connie N. Hess et al.
AMERICAN HEART JOURNAL (2017)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE
Paul S. Jellinger et al.
ENDOCRINE PRACTICE (2017)
The relationship between Lp(a) and CVD outcomes: a systematic review
Carol A. Forbes et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
Michelle L. O'Donoghue et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Baseline LDL-C and Lp(a) Elevations Portend a High Risk of Coronary Revascularization in Patients after Stent Placement
Anping Cai et al.
DISEASE MARKERS (2013)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Robert Clarke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
分享论文
